Breaking News

Tizona Licenses Ligand’s OmniAb Transgenic Platforms

Will use OmniRat, OmniMouse and OmniFlic to generate fully human mono- and bispecific antibodies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand Pharmaceuticals has entered into a worldwide license agreement with Tizona Therapeutics, an immunology company developing therapies for cancer and autoimmune disease, for its OmniAb transgenic animal platforms. Tizona will use the OmniRat, OmniMouse and OmniFlicplatforms to generate fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual platform access payments and patent filing fees, and clinical milestones and royalties for each successful OmniAb antibody...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters